A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck

Oral Oncology

Volumn 51, Issue 3, 2015, Pages 279-286

  Patil, Vijay Maruti ^a   Noronha, Vanita ^a   Joshi, Amit ^a   Muddu, Vamshi Krishna ^a   Dhumal, Sachin ^a   Bhosale, Bharatsingh ^a   Arya, Supreeta ^a   Juvekar, Shashikant ^a   Banavali, Shripad ^a   D'Cruz, Anil ^a   Bhattacharjee, Atanu ^b   Prabhash, Kumar ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b Malabar Cancer Centre   (India)

Author keywords

Chemotherapy; Cisplatin; Head and neck cancer; Metronomic administration; Oral cancer; Palliative

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CREATININE; ERLOTINIB; METHOTREXATE; PACLITAXEL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPIRATION PNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DYSPHAGIA; ELECTROCORTICOGRAPHY; FATIGUE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOKALEMIA; HYPONATREMIA; INOPERABLE CANCER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METRONOMIC CHEMOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEAD AND NECK NEOPLASMS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CYCLOOXYGENASE 2 INHIBITORS; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZOLES; RISK FACTORS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84923106874     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.12.002     Document Type: Article

References (34)

1. Y. More, and A.K. D'Cruz Oral cancer: review of current management strategies Natl Med J India 26 3 2013 152 158
2. K.R. Coelho Challenges of the oral cancer burden in India J Cancer Epidemiol 2012 2012 701932 10.1155/2012/701932
3. R. Dikshit, P.C. Gupta, and C. Ramasundarahettige Cancer mortality in India: a nationally representative survey Lancet 379 9828 2012 1807 1816 10.1016/S0140-6736(12)60358-4
4. R. Sankaranarayanan Oral cancer in India: an epidemiologic and clinical review Oral Surg Oral Med Oral Pathol 69 3 1990 325 330
5. N.P. Trivedi, V.D. Kekatpure, N.N. Trivedi, and M.A. Kuriakose Head and neck cancer in India: need to formulate uniform national treatment guideline? Indian J Cancer 49 1 2012 6 10 10.4103/0019-509X.98907
6. J.T. Parsons, W.M. Mendenhall, S.P. Stringer, N.J. Cassisi, and R.R. Million An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity Int J Radiat Oncol Biol Phys 39 1 1997 137 148
7. R.J. Amdur, J.T. Parsons, W.M. Mendenhall, R.R. Million, S.P. Stringer, and N.J. Cassisi Postoperative irradiation for squamous cell carcinoma of the head and neck: an analysis of treatment results and complications Int J Radiat Oncol Biol Phys 16 1 1989 25 36
8. B.E. Brockstein Management of recurrent head and neck cancer: recent progress and future directions Drugs 71 12 2011 1551 1559 10.2165/11592540-000000000-00000
9. J.B. Vermorken, R. Mesia, and F. Rivera Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 11 2008 1116 1127 10.1056/NEJMoa0802656
10. D.N. Ignacio, J.J. Griffin, M.G. Daniel, M.T. Serlemitsos-Day, F.A. Lombardo, and T.A. Alleyne An evaluation of treatment strategies for head and neck cancer in an African American population West Indian Med J 62 6 2013 504 509
11. M.A. Molina, M.C. Cheung, and E.A. Perez African American and poor patients have a dramatically worse prognosis for head and neck cancer: an examination of 20,915 patients Cancer 113 10 2008 2797 2806 10.1002/cncr.23889
12. P.E. Goss, K. Strasser-Weippl, and B.L. Lee-Bychkovsky Challenges to effective cancer control in China, India, and Russia Lancet Oncol 15 5 2014 489 538 10.1016/S1470-2045(14)70029-4
13. N. André, S. Banavali, Y. Snihur, and E. Pasquier Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol 14 6 2013 e239 248 10.1016/S1470-2045(13)70056-1
14. S.-W. Park, H.-S. Kim, J.-W. Hah, W.-J. Jeong, K.-H. Kim, and M.-W. Sung Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines Anticancer Drugs 21 9 2010 823 830 10.1097/CAD.0b013e32833dada8
15. K.A. Pathak, A.S. Juvekar, and D.K. Radhakrishnan In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy Indian J Cancer 44 4 2007 142 146
16. R.B. Pai, R.M. Lalitha, S.B. Pai, S.V. Kumaraswamy, N. Lalitha, and M.K. Bhargava Analysis of in vitro and in vivo sensitivity of oral cancer cells to methotrexate Exp Oncol 31 2 2009 118 120
17. S. Glück, H. Lau, J. Mackinnon, R. Syme, and D. Glück Metronomic therapy in recurrent and metastatic chemoresistant SCCHN: data from a pilot study Biomed Pharmacother 59 2005 S319
18. V. Patil, V. Noronha, V. Krishna, A. Joshi, and K. Prabhash Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers Clin Oncol R Coll Radiol G B 25 6 2013 388 10.1016/j.clon.2013.01.002
19. V. Patil, V. Noronha, A.K. D'cruz, S.D. Banavali, and K. Prabhash Metronomic chemotherapy in advanced oral cancers J Cancer Res Ther 8 Suppl 1 2012 S106 110 10.4103/0973-1482.92223
20. R.P. Morton, F. Rugman, and E.B. Dorman Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial Cancer Chemother Pharmacol 15 3 1985 283 289
21. R.E. Wittes, E. Cvitkovic, J. Shah, F.P. Gerold, and E.W. Strong CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck Cancer Treat Rep 61 3 1977 359 366
22. A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. Br J Cancer. vol. 61(2), 1990. p. 311-5.
23. M. Clavel, J.B. Vermorken, and F. Cognetti Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC head and neck cancer cooperative group Ann Oncol Off J Eur Soc Med Oncol ESMO 5 6 1994 521 526
24. J.B. Vermorken, and P. Specenier Optimal treatment for recurrent/metastatic head and neck cancer Ann Oncol Off J Eur Soc Med Oncol ESMO 21 Suppl 7 2010 252 261 10.1093/annonc/mdq45
25. C. Jacobs, G. Lyman, and E. Velez-García A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck J Clin Oncol Off J Am Soc Clin Oncol 10 2 1992 257 263
26. A.A. Forastiere, B. Metch, and D.E. Schuller Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest oncology group study J Clin Oncol Off J Am Soc Clin Oncol 10 8 1992 1245 1251
27. M.K. Gibson, Y. Li, and B. Murphy Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern cooperative oncology group J Clin Oncol Off J Am Soc Clin Oncol 23 15 2005 3562 3567 10.1200/JCO.2005.01.057
28. K.K. Ang, and E.M. Sturgis Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma Semin Radiat Oncol 22 2 2012 128 142 10.1016/j.semradonc.2011.12.004
29. H.M. Walline, C. Komarck, and J.B. McHugh High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods JAMA Otolaryngol - Head Neck Surg 139 12 2013 1320 1327 10.1001/jamaoto.2013.5460
30. I.J. Higginson, and G.J. Sen-Gupta Place of care in advanced cancer: a qualitative systematic literature review of patient preferences J Palliat Med 3 3 2000 287 300 10.1089/jpm.2000.3.287
31. W.G. Evans, T.M. Cutson, K.E. Steinhauser, and J.A. Tulsky Is there no place like home? Caregivers recall reasons for and experience upon transfer from home hospice to inpatient facilities J Palliat Med 9 1 2006 100 110 10.1089/jpm.2006.9.100
32. The Lancet Oncology Is India ready to lead the battle for fair access to medicines? Lancet Oncol 14 6 2013 437 10.1016/S1470-2045(13)70197-9
33. D. Collingridge, and R. Sullivan Affordable cancer care: pipedream or achievable reality? Lancet Oncol 15 3 2014 257 258 10.1016/S1470-2045(14)70062-2
34. S. Limaye, S. Riley, and S. Zhao A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN) Oral Oncol 49 8 2013 835 841 10.1016/j.oraloncology.2013.04.010